VSee Health, Inc. Stock Price, News & Analysis

VSee Health (NASDAQ:VSEE) announced record-setting revenue growth and the elimination of over $5 million in legacy SPAC debt on October 23, 2025. The company said this debt removal strengthens its balance sheet, bolsters creditor confidence, and helps ensure compliance with NASDAQ listing requirements. Management framed the move as positioning VSee Health for sustained long-term growth and noted shareholder support as a key factor in the milestone.

VSee Health (Nasdaq:VSEE) announced a multi-year teleradiology contract executed May 7, 2025, with service delivery beginning June 15, 2025, for a premier Level 1 hospital system.

The deal is projected to generate approximately $10 million in gross revenue over the next two years, with provisions for an additional $5M+ in potential revenue, and is described as set to double annual recurring revenue. Revenue recognition has begun and will appear in the company's upcoming Q3 10-Q. The release lists a quoted share price of $0.479 and market cap of $8,123,227.67 as of October 20, 2025.

VSee Health (Nasdaq:VSEE) reported Second Quarter 2025 results for the three months ended June 30, 2025, with revenue of $3.4 million, up 98% year-over-year and a rise in gross profit margin from 45% to 47%. The company reported improved operating cash use in the first six months of 2025 at $765,094 versus $2,594,214 a year earlier. Cash flow from financing for H1 2025 was $746,040 compared with $3,597,841 in H1 2024, and investing cash use was minimal at $15,466.

The company attributes strong revenue growth to the acquisition and integration of iDoc Telehealth, expanded customer relationships, and new services that improved margins, while noting integration challenges remain.

VSee Health (NASDAQ:VSEE) has received approval from Nasdaq to maintain its listing status, subject to specific conditions. The company must file its delayed Q1 and Q2 2025 quarterly reports by October 15, 2025, and demonstrate compliance with Nasdaq's Equity Rule by December 1, 2025.

The company is actively working with its auditors to complete and submit the required financial reports within the extension period granted by the Nasdaq Hearings Panel. Additionally, VSee Health has confirmed its commitment to addressing and meeting the net equity requirements within the specified timeframe.

VSee Health (Nasdaq:VSEE) announced significant expansion of its teleradiology services, having implemented 17 out of 25 planned hospital integrations by August 2025. The company secured contracts with a major vendor for 22 hospitals, with an additional 3 hospitals recently awarded, bringing the total expected annual recurring revenue (ARR) to approximately $3 million.

Following a successful pilot of 3 hospitals in May 2025, VSee rapidly expanded to 17 hospitals within three months. The company's teleradiology platform offers real-time interpretation of medical imaging, 24/7 coverage, and seamless integration with existing hospital systems, enabling remote radiologist consultations and improved diagnostic efficiency.

VSee Health (NASDAQ:VSEE) announced it is appealing a NASDAQ Staff Determination to delist its common stock from the Nasdaq Capital Market. The delisting notice was received on August 5th, 2025, citing non-compliance with filing requirements for the 2024 Annual Report and Q1 2025 Quarterly Report.

The company has requested a hearing before the Nasdaq Listing Qualifications Panel, which automatically stays the delisting for 15 days. VSee Health plans to request an extended stay pending the hearing. If the appeal is unsuccessful, the company's stock could move to trading on the OTC Bulletin Board.

VSee Health (NASDAQ:VSEE) has launched its new AI Doctor Notes solution, partnering with Tele911, the largest national telemedicine emergency room diversion service. The AI-powered solution has achieved a remarkable 93% reduction in physician documentation time, cutting charting time from 15 minutes to under 1 minute per visit.

The system automatically generates structured SOAP notes with ICD codes in two clicks, integrating seamlessly with Tele911's virtual emergency care workflow. The solution is available both as an integrated feature in VSee's digital health platform and as a standalone product compatible with any EHR system.

VSee Health (NASDAQ:VSEE) has launched its new AI Doctor Notes solution, partnering with Tele911, the largest national telemedicine emergency room diversion service. The AI-powered system has demonstrated a remarkable 93% reduction in documentation time, cutting physician charting time from 15 minutes to under 1 minute per visit.

The solution automatically transcribes visits and generates structured SOAP notes with ICD codes in two clicks. It's available both as an integrated feature in VSee's digital health platform and as a standalone solution compatible with any EHR. The integration aims to enhance clinical efficiency and allow physicians to focus more on patient care rather than administrative tasks.

VSee Health has been selected to support a NIH-funded Phase 3 clinical trial studying stroke recovery telerehabilitation at UCLA. The trial involves 29 hospitals and 202 patients, evaluating a 6-week gamified home-based telerehab program to improve arm functionality in stroke survivors. The study aims to reduce costs related to transportation, caregiver burdens, and hospital readmissions. VSee's HIPAA-compliant platform will facilitate secure delivery of interventions in the $328M global stroke rehab market. The trial, beginning Q3 2025, represents a significant milestone after twelve years of development and builds on VSee's involvement in previous Phase 1 and 2 studies. Success could lead to Medicare and private payer reimbursement while opening opportunities for telerehabilitation in other neurological conditions.